Navigation Links
Devicor™ Medical Products, Inc. Completes Acquisition of Neoprobe's Gamma Detection Devices
Date:8/17/2011

CINCINNATI, Aug. 17, 2011 /PRNewswire/ -- Devicor™ Medical Products, Inc. (Devicor), a portfolio company of GTCR, a leading private equity firm, announced today the completion of its previously announced agreement to acquire the neoprobe® gamma detection system (GDS) products and related assets from Neoprobe Corporation.

Devicor previously provided distribution and marketing services to Neoprobe for the GDS portfolio. Financial terms of the agreement included $30 million cash at close plus up to an additional $20 million in royalties based on revenue milestones. The sale was approved by Neoprobe's shareholders on August 15.

"We are excited to complete this agreement with Neoprobe and believe this is a significant step toward our goal of building a market leading medical device business," says Devicor CEO Tom Daulton. "We look forward to welcoming to Devicor all of the dedicated Neoprobe employees responsible for this growing product portfolio, as we plan to expand the business further through our global direct sales platform and additional R&D investment."

The acquisition of the neoprobe® GDS line comes approximately a year after Devicor's acquisition of Ethicon Endo-Surgery's (EES) Breast Care business, Mammotome, which sells products designed to help doctors detect and diagnose breast cancer. GTCR invested additional equity capital in Devicor to finance a portion of the purchase price of the neoprobe® GDS assets.

"The funding of additional equity capital by GTCR to support our growth is an excellent example of the strong partnerships GTCR forms with management teams to acquire and expand successful companies in healthcare and other industries," says Jonathan Salkin, Devicor's Executive Vice President of Corporate Development & Strategy.  

The Mammotome® product portfolio is sold in 50 countries around the world and includes the Mammotome® Breast Biopsy System as well as tissue markers for breast disease diagnostic sampling and management. Mammotome has distributed and marketed Neoprobe's line of gamma detection systems since 2000, as part of EES and then continuing as part of Devicor.

About Devicor™ Medical Products, Inc.

Devicor, the parent corporation of Mammotome, is a fast-growing global company dedicated to acquiring and growing healthcare companies. With an initial focus on the breast cancer market, the company is dedicated to building a global business through the investment in, and development of, tools and technologies that facilitate minimally invasive medical procedures. For more information, please visit www.devicormedical.com.

Mammotome, headquartered in Sharonville, Ohio, has more than 300 employees around the globe. The company is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Sold in more than 50 countries around the world, the Mammotome® product portfolio includes the Mammotome® Breast Biopsy System and tissue markers (MammoMARK®, MicroMARK®, and CorMARK®) used in breast disease diagnostic sampling and management. Since its introduction in 1995, more than 3.4 million women have had a minimally invasive breast biopsy in stereotactic, ultrasound or MRI-guidance imaging using the Mammotome® Biopsy System. For more information, please visit www.mammotome.com.

About Neoprobe Corporation

Neoprobe is a biomedical company focused on enhancing oncology patient care and improving patient benefit. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR.  Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. For more information, please visit www.neoprobe.com.

About GTCR

Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare and Information Services & Technology industries. The Chicago-based firm pioneered the "Leaders Strategy" – finding and partnering with world-class leaders as the critical first step in identifying, acquiring and building market-leading companies through acquisitions and organic growth. Since its inception, GTCR has invested more than $8.5 billion in over 200 companies. For more information, please visit www.gtcr.com.


'/>"/>
SOURCE Devicor Medical Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Devicor™ Medical Products, Inc. Agrees to Acquire Neoprobes Gamma Detection Devices
2. Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011
3. Beth Israel Deaconess Medical Center Treats 2,000th Patient with the CyberKnife System
4. China Nuvo Solar Target Acquisition SurgLine Updates OptiMedical Corp.s Sales Forecast in Excess of $10,000,000
5. China Medical Technologies Reports First Fiscal Quarter Financial Results
6. Vycor Medical, Inc. Restatement of Financial Statements
7. FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices
8. CCS Medical Appoints Michael A. Sicuro as Executive Vice President and Chief Financial Officer
9. Dehaier Medical Announces Record Second Quarter 2011 Financial Results
10. Medical Device Marketing Groups Focus More Resources on Tactical Activities When Compared to Pharmaceutical Counterparts
11. DMES, Inc. Announces 100 Percent Growth for Online Medical Supply Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, ... appointment of Mark Weinberg , MD MBA as Chief Medical ... , USA . ... Dr Weinberg has spent more than 17 years ... 20" pharma companies to micro-cap biotech. Over the course of his ...
(Date:1/19/2017)... The Global Therapy Partnering Terms and Agreements ... deals and agreements entered into by the world,s leading ... Top deals by value - Deals listed by company ... The report provides understanding and access to the partnering ... healthcare companies. The report provides an analysis of ...
(Date:1/19/2017)... Jan. 19, 2017 This report on the ... future scenario of the global market. Large number of ... Severe chronic constipation is a major side effect of ... Hence, novel targeted therapy has been prescribed to treat ... of targeted medicines, and growing awareness about the therapy ...
Breaking Medicine Technology:
(Date:1/20/2017)... Texas (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... the bible in homes across the world. Yisrayl says this generation is a time like ... is to turn to the Bible. , Yisrayl says he does not want to sound ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Lice Troopers, the ... cases in families with school-aged children since the holiday season. , “It happens ... with their families, sharing hugs and taking photos, which is the head-to-head gateway that ...
(Date:1/20/2017)... ... ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are fully ... - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 lens ... and light leak transitions have a very high-dynamic range for super smooth falloff. Simply ...
(Date:1/20/2017)... ... 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on ... of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of ... 19 years of age, he joined the Navy and got married right out of boot ...
(Date:1/20/2017)... ... 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the ... a mother of three in Oklahoma City, and a devoted woman of faith. , ... has been in the back of my mind for years, but actually doing it might ...
Breaking Medicine News(10 mins):